I don’t think the difference between the way the companies are approaching GvHD is difficult to explain. But I do agree with you that it could be made clearer, and an update following MSB’s approval would be welcome. I would expect them to be touring the US and EU with a new presentation including this. But as you say, we will find out relatively quickly given the Bioweek conference is only 2 weeks away, so arguing the point is redundant.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 307684 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 19285 | 2 |
View Market Depth
| Last trade - 10.58am 17/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable